UCB confirms good 2005 performance of Zyrtec in US and Xyzal | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

UCB confirms good 2005 performance of Zyrtec in US and Xyzal

Brussels, Belgium - January 19, 2005 - Following Pfizer's quarterly earnings release, UCB confirms that Zyrtec continues to strengthen its leadership position as the number one most prescribed branded antihistamine in the US in new prescriptions. The US in-market sales of Zyrtec have reached USD 1,362 million during the year 2005, showing a 6 % increase against the same period in 2004.

The worldwide sales of Xyzal increased by 21% during the year 2005 versus the same period in 2004, resulting in a leadership position in seven European countries[1].

IMS[2] market share for Xyzal in Europe reached 16% compared to 15% a year earlier.


About UCB

UCB (www.ucb-group.com) is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specialising in the fields of central nervous system disorders, inflammatory diseases, and oncology. UCB key products are Keppra® (antiepileptic), Xyzal® and Zyrtec® (antiallergics), Nootropil® (cerebral function regulator), Tussionex® (antitussive) and Metadate(TM) / Equasym XL(TM) (attention deficit/hyperactivity disorder). UCB employs over 8,500 people operating in over 40 countries. UCB is listed on Euronext Brussels (UCB / UCBBt.BR / UCB BB).

For further information please contact:

Jean-Christophe Donck

Vice President

Corporate Communication & Investor Relations

Phone +32 2 559 9588

Fax +32 2 559 9571

Email jc.donck@ucb-group.com

[1] IMS, Total R6A Antihistamine market share in treatment days (October 2005)

[2] IMS, Total R6A Antihistamine market share in value (EU5 Markets - November 2005)

Asset Download

Stay up-to-date on the latest news and information from UCB